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Abstract
Background: Oral squamous cell carcinoma (OSCC) is associated with a poor 5-year survival rate. In general,
patients diagnosed with small tumors have a fairly good prognosis, but some small tumors have an aggressive
behavior leading to early death. There are at present no reliable prognostic biomarkers for oral cancers. Thus, to
optimize treatment for the individual patient, there is a need for biomarkers that can predict tumor behavior.
Method: In the present study the potential prognostic value of plectin was evaluated by a tissue microarray (TMA)
based immunohistochemical analysis of primary tumor tissue obtained from a North Norwegian cohort of 115 patients
diagnosed with OSCC. The expression of plectin was compared with clinicopathological variables and 5 year survival.
Results: The statistical analysis revealed that low expression of plectin in the tumor cells predicted a favorable
outcome for patients with non-metastatic disease (p = 0.008). Furthermore, the expression of plectin was found
to correlate (p = 0.01) with the expression of uPAR, which we have previously found to be a potential prognostic
marker for T1N0 tumors.
Conclusions: Our results indicate that low expression of plectin predicts a favorable outcome for patients with
non-metastatic OSCC and the expression level of plectin may therefore be used in the treatment stratification for
patients with early stage disease.
Background
Squamous cell carcinoma (SCC) accounts for more
than 90 % of the malignant neoplasms of the head and
neck region [1, 2]. Head and neck SCC (HNSCC) have
a 5-year survival rate of approximately 50 %, [3, 4] and
are ranked as the eighth leading cause of cancer death
worldwide [5].
OSCC includes tumors located in the mobile tongue,
floor of the mouth, buccal mucosa, gingival rim and the
hard and soft palate. The most widely used classification-
system of OSCC is the TNM-system by the Union for
International Cancer Control [6]. This system is used to
describe the anatomical extent of the disease at diagnosis
based on primary tumor size and extent of tumor growth
(T), regional lymph node metastasis (N) and distant
metastasis (M), and is the basis for stage grouping these
patients [7, 8]. By morphological assessment, tumors are
graded as well, moderate and poorly differentiated [1].
The TNM-classification, and to a lesser extent, the grade
of differentiation, are often used as predictors for out-
come. However, OSCCs are molecularly heterogeneous
and tumors with identical TNM-classification and differ-
entiation grade may differ in aggressiveness and response
to treatment [7, 9]. This unpredictable behavior raises the
need for a diagnostic tool that can provide more reliable
prognostic information.
A risk model based on histological analysis of the tu-
mors has been proposed [10–12]. However, in a recent
study this model did not predict the outcome of patients
with tongue SCC [13]. Several previous reports have pro-
posed different biomarkers, such as p53, EGFR, Ki67 and
E-cadherin as prognostic markers for OSCC, [14–16]
though none have been implemented in clinical practice.
In an attempt to find new and better prognostic markers
we have in this study focused on plectin Plectin is a large
intracellular cytoskeletal linker protein (>500-kDa) that
* Correspondence: Sonja.steigen@unn.no
2Department of Medical Biology - Tumor Biology Research Group, Faculty of
Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway
3Department of Clinical Pathology, University Hospital of North Norway,
N-9038 Tromsø, Norway
Full list of author information is available at the end of the article
© 2015 Rikardsen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rikardsen et al. BMC Oral Health  (2015) 15:98 
DOI 10.1186/s12903-015-0084-9
has been found to be important in cytoskeletal network
organization. It is expressed in normal skin and in the epi-
thelial lining of the gastrointestinal-tract, muscle cells and
endothelial cells of vessels, [17] as well as in cancer arising
in the esophagus, stomach, lung, pancreas and the oral
cavity [17, 18]. Plectin is localized at the inner side of the
plasma membrane where it is associated with intermediate
filaments (IF), microtubules and microfilaments [19]. In
hemidesmosomes, plectin interacts with the cytoplasmatic
tail of the integrin β4 subunit. Defects in the plectin gene
have been found in the severe, hereditary, skin blistering
hereditary disease epidermolysis bullosa simplex, empha-
sizing the importance of the protein in normal epithelial
cells [20]. Plectin affects mechanical, as well as dynamic
properties of the cytoskeleton, and (at least in keratino-
cytes) plectin-deficiency has been shown to result in in-
creased migration rates probably through activation of the
Erk1/2 pathway [21]. In a study investigating HNSCC,
Katada et al. found that the survival rate of patients with
high plectin expression in their cancer cells was signifi-
cantly decreased, and the frequency of recurrences signifi-
cantly increased, compared to patients with low plectin
expression [22].
In a recent study we showed that the urokinase plas-
minogen activator receptor (uPAR) and plasminogen ac-
tivator inhibitor-1 (PAI-1) may be prognostic markers in
early stage OSCC [23]. uPAR is a constituent of the plas-
minogen activator (PA) system, and both urokinase plas-
minogen activator (uPA) and uPAR are linked to
increased proteolytic activity and migration of cancer
cells. uPA converts plasminogen into the active serine
protease plasmin, a broad spectrum protease that can
degrade many different types of extracellular matrix pro-
teins in addition to activate latent growth factors and
matrix metalloproteases [24, 25]. By binding of uPA to
uPAR, cancer cells can direct the proteolytic activity to
the cell surface [26]. As with plectin, the increased ex-
pression of uPAR has been linked to the phenomenon
epithelial-mesenchymal transition (EMT) [27–29].
In this TMA-based study, low expression of plectin
was found to be a marker for a favorable prognosis in
non-metastatic OSCC. Plectin and uPAR showed similar
staining patterns in the tumors and there was a signifi-
cant correlation between plectin and uPAR expression.
Methods
Specimens
This was a retrospective study using formalin fixed, paraffin
embedded tumor samples from 115 patients with histologi-
cally verified primary OSCC in the period 1986–2002 col-
lected from the archives of the Department of Clinical
Pathology, University Hospital of North Norway. To secure
a homogenous cohort, tumors with verrucous growth pat-
terns as well as tumors from patients with previous cancer,
or prior radiotherapy to the head and neck area were ex-
cluded. All patients presented with primary disease located
in the oral cavity, including mobile tongue, floor of the
mouth, buccal mucosa, gingiva and hard and soft palate.
Relevant clinical data and TNM-classification were re-
trieved from patients’ files, including pathology reports, Sta-
tistics of Norway and the Cause of Death Registry. The N
and M statuses were determined by clinical and radiological
examination. The normal tongue mucosa tissue was ob-
tained from tissue adjacent to the tumor tissue. The study
was approved by the Regional Committees for Medical and
Health Research Ethics, Northern Norway (No. 22/2007).
The patient information was de-identified prior to analysis.
The ethics committee deemed it unnecessary to obtain
written or oral consent from the participating patients.
Tissue microarray (TMA)
A morphologically representative region of each tumor
was identified on a hematoxylin and eosin (HE)-stained
slide, and cores for the TMA were harvested from the
corresponding tissue block using a Beecher Instruments
Micro Tissue Arrayer. Eight cores of 0.6 mm were taken
from the selected regions of the donor block of each
tumor and inserted into recipient paraffin microarray
blocks. Four μm thick sections of the fixed, paraffin em-
bedded TMA tissue were cut with a microtome and
placed on Superfrost slides. HE-staining and immuno-
histochemical cytokeratin-staining was performed to ver-
ify the presence of tumor tissue.
We experienced a loss of 16.5 % of the cores during
preparation, and of the preserved cores, 8.4 % contained
too few tumor cells to be evaluated. This loss due to
technical issues is moderate compared to other reports
[30, 31]. From each patient a mean number of 3.82 cores
stained and evaluated for plectin expression.
Evaluated from each patient was 3.82.
Immunohistochemistry (IHC)
All slides were deparaffinised and rehydrated. The plectin
antigen retrieval was enhanced by boiling in a pressurized
system with 10 mM citrate buffer (pH 7.0). Further, the
slides were incubated 30 min with 3 % H2O2 to block en-
dogenous peroxidase activity, and incubated one hour with
10 % goat serum (Dako, Glostrup, Denmark) in phosphate
buffered saline (PBS) (Dako, Glostrup, Denmark) to reduce
unspecific staining. Rabbit primary monoclonal antibody
against plectin (ab32528, Abcam, Cambridge, MA) was di-
luted 1:200 in Dako antibody diluent (S3022, Dako,
Glostrup, Denmark), and incubated overnight at 4 °C. Sub-
sequently, bound antibodies were visualized using the anti-
rabbit Envision Plus System (K4011, Dako, Glostrup,
Denmark). The slides were washed in PBS w/0.1 % Tween-
20 with high concentrations of salt (0.4 M NaCl) and
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pH 6.0 (PBSTS6) after incubation with primary and sec-
ondary antibodies.
The anti-plectin antibody (ab32528) has previously been
described and validated as a good marker for pancreatic
adenocarcinoma [18]. As a negative control, pancreatic
carcinoma tissue was treated according to the same stain-
ing protocol, but the primary antibody was omitted. No
staining was seen indicating that the secondary antibody
gave no unspecific staining in the tissue (data not shown).
Staining of normal oral mucosa showed specific and
strong staining of muscle tissue in blood vessels, serving
as positive control.
The uPAR staining was performed according to previ-
ous describes protocols [23].
Immunohistochemical scoring
All cores were examined by an experienced patholo-
gist (SES) and a trained head and neck surgeon (OR)
without knowledge of clinical outcome. The scoring
was semi-quantitative, [32, 33] and the staining index
(SI) calculated as a product of staining intensity (none
(0), weak (1), moderate (2) or strong (3)) and propor-
tion of positive tumor cells (no staining (0), <10 %
(1), 10–50 % (2), 51–80 % (3) or >80 % (4)). Thus,
the SI for each core differed from a minimum value
of zero to a maximum of 12, and the patient’s final
score was the mean SI of all cores evaluated. Tumors
with score above the median value were classified as
high expressers’, while those with score under median
value were classified as having a low expression of
the biomarker.
Immunofluorescence (IF)
For IF analysis the slides were pretreated as described in
the IHC protocol for plectin. A rabbit polyclonal anti-
plectin antibody (ab83497, Abcam, Cambridge, MA) rec-
ommended for IF was used. The antibody was diluted
1:10 in Dako antibody diluent (S3022, Dako, Glostrup,
Denmark) and incubated for 3 h at room temperature.
After the slides had been washed with PBSTS6, they were
incubated overnight at 4 °C with the mouse monoclonal
anti-human uPAR antibody (#3936, Sekisui Diagnostica,
Stamford, CT, USA) at a 1:10 dilution in a buffer of 10 %
goat serum (Dako North America, Carpintera, CA, USA)
in PBS with 1 % BSA and 0.3 % Tween-20, pH 6.0. After
incubation the slides were washed with PBSTS6. The sec-
ondary antibodies (Alexa Fluor 488, goat-anti rabbit,
A11034 and Alexa Fluor 647, goat-anti mouse, A21236,
Invitrogen, Carlsbad, CA) were mixed and diluted 1:200 in
PBS. The slides were mounted and counterstained with
DAPI antifade (DAPI in Fluorgard, 0.5 g/ml, Insitus,
Albuquerque, NM) and sealed with nail polish. The slides
were observed and photographed using Leica TCS SP5
confocal laser microscope with Leica Application Suite
Advanced Fluorescence software (Leica Microsystems AG,
Wetzlar, Germany).
The specificity of the polyclonal anti-plectin antibody
(ab83497) used in the immunofluorescence staining was
tested by staining pancreatic adenocarcinoma. Similar to
the monoclonal anti-plectin antibody, the polyclonal
anti-plectin antibody specifically stained pancreatic can-
cer cells. Furthermore, Western blotting of whole muscle
cell lysate showed that the antibody gave a band of the
approximately 500 kDa corresponding to the size of
plectin (data not shown).
Statistics
All data were tabulated and analyzed using the IMB SPSS
Statistics (Chicago, IL), version 21. Associations between
different categorical variables were assessed by the
Pearson`s chi-square test. Univariate analyses of the differ-
ent variables’ influence on time to disease specific survival
were performed using the Kaplan-Meier method, and stat-
istical significance between categories was estimated by the
log-rank test. Statistically significant values from COX
univariate analyses were entered into a multivariate analysis
using the backward stepwise Cox regression model. Disease
specific death (DSD) was defined as patients dying form
OSCC and not from unrelated conditions. These data were
obtained from the “Cause of Death registry in Norway.
Correlation between bivariates was calculated with
Spearman’s rho. The cut-off for low and high expression for
each biomarker was set at the median value of the patient’s
final score, and was 5.60 for plectin and 5.63 for uPAR. All
results were considered significant if p < 0.05, and reported
according to the REMARK guidelines by McShane et al.
[34] The starting point was defined as time of diagnosis,
and the last day of follow up was January 1st, 2012.
Results
In the present study the prognostic value of plectin in
OSCC was evaluated by a TMA-based immunohistochemi-
cal analysis of primary tumor tissue obtained from a North
Norwegian cohort of 115 patients. The cohort consisted of
64 men and 51 women, with a mean age of 65.2 years (men
64.4/women 66.0) at diagnosis [23]. The majority of the
cases presented with small tumors (T1, 34 % or T2, 37 %),
no lymph node metastasis (N0, 63 %) and a well or moder-
ately differentiated tumor (90 %). As expected, tumor size
(T) and the presence of lymph node metastasis (N+) corre-
lated significantly with disease specific death (DSD), while
the grade of differentiation did not.
Immunohistological staining pattern
Plectin scarcely stained normal tongue mucosa that served
as control material, while the blood vessels in the under-
lying stroma displayed stronger staining (Fig. 1a). In
plectin-positive OSSC tumors the staining was relatively
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homogeneous throughout the tumor (Fig. 1b). The cancer
cells were highly positive while the adjacent extracellular
matrix showed less reactivity. The staining of the cancer
cells was mainly confined to the plasma membrane (Fig. 2),
but cytoplasmic staining was also observed in a relatively
large proportion of the cores.
Survival
For patients without lymph node metastasis (N0), at any
T-stage, the risk of dying of the disease within 5 years was
significantly decreased in patients with low plectin ex-
pressing tumors compared to those with high plectin ex-
pression (p = 0.008) (Table 1 and Fig 3). Also, for the
patients with T1-tumors, independent of N-status, the
statistical analyses revealed a significantly reduced risk for
DSD in those who had tumors with low plectin expression
(p = 0.031). As expected, given the preceding results, pa-
tients with T1N0 tumors with low plectin expression had
an excellent outcome as all these patients were still alive
after 5 years (p < 0.001). In a multivariate analysis of the
N0-cases including plectin and tumor size (T1 vs T2-4),
only high plectin expression was a significant independent
predictor of increased DSD (p = 0.014, HR 3.674, CI 95 %
1.305-10.344).
Correlation of plectin and uPAR expression
We have recently shown that patients with T1N0 tumors
expressing low levels of uPAR have a significantly reduced
DSD compared to those with a higher uPAR expression.
To investigate the distribution of expression of uPAR and
plectin in the tumors we did a chi-square test, and found
that a significant number of the tumors that were high ex-
pressers of uPAR also were high expressers of plectin, and
those with low expression of uPAR generally were low ex-
pressers of plectin. This correlation was significant with a
correlation coefficient of 0.769 (p = 0.01) as shown in a
scatter plot in Fig. 4. Double immunofluorescence staining
was performed on some selected tumors to investigate
whether plectin and uPAR were co-located within the
same cells, co-expressed by the same cells, or located to
the same tumor regions. The immunofluorescence
showed that the plectin and uPAR staining was localized
to the same areas of the tumor (Fig. 5). As expected, the
immunofluorescence staining confirmed that plectin was
Fig. 1 Immunohistochemical staining for plectin of normal tongue mucosa (a) and oral squamous cell carcinoma (b). The normal mucosa showed
only faint staining while the blood vessels in the stroma were strongly stained. The staining of plectin positive tumor cells was strong, and the stroma
showed almost no staining
Fig. 2 Immunhistochemical staining pattern in TMA cores of oral squamous cell carcinoma. Plectin staining was mainly at the plasma membrane,
but also some cytoplasmic staining was seen
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found mainly at the plasma membrane while uPAR was
mainly localized in the cytoplasm.
Discussion
Surgery is the primary treatment for cancer in the oral
cavity, and is often combined with radiotherapy while
chemotherapy is more often applied as palliative treatment
in late phase of the treatment [35–37]. Side effects of the
treatment for oral cancer may be devastating for the pa-
tient’s quality of life, [38], and therefore it is important to
avoid harmful overtreatment with radiotherapy of patients
with small tumors with favorable prognosis. Decisions
concerning the extent of treatment of patients with early
stage OSCC are often difficult. Still, the choice of treat-
ment is mainly based on TNM-stage which does not dis-
criminate between aggressive and more indolent tumors.
Several studies on potential biomarkers for treatment
stratification have shown promising results, but so far no
such biomarkers have been implemented in clinical prac-
tice. In the present study we have investigated the poten-
tial role of plectin as a prognostic biomarker. To our
knowledge, the prognostic value of plectin in OSCCs
has previously only been studied by Katada et al. who
investigated a cohort of 62 HNSCC, among them 23
from the oral cavity [22]. Although the cohort was small
and heterogeneous, they found that the survival was sig-
nificantly decreased when the tumor cells expressed
high levels of plectin. Our cohort is larger and com-
posed only of tumors from the oral cavity and therefore
more homogeneous. In accordance with the results
from Katada et al., we found that low expression of plec-
tin in the tumor cells predicts a favorable outcome, but
only in patients with early stage disease.
We have previously found that low expression of
uPAR correlated with reduced DSD for OSCC patients
with T1N0 tumors, and that uPAR therefore might be a
Fig. 3 Kaplan-Meier plot. The figure illustrates the difference in survival among N0-patients with high and low expression of plectin respectively
Table 1 Expression of plectin in the whole cohort, the N0, T1 and
T1N0 patients at time of diagnosis. The number of patients with a
5 year disease specific death (DSD) is given in numbers and also
as percentage of total in each group of total in each group
Plectin
Low expression High expression DSDp
All patientsa N (% of total) 55 56
5-year DSD 19 (35 %) 25 (45 %) 0.198
N0-casesb N (% of total) 36 32
5-year DSD 5 (14 %) 13 (41 %) 0.008*
T1-casesc N (% of total) 23 16
5-year DSD 2 (9 %) 6 (38 %) 0.031*
T1N0-casesd N (% of total) 19 9
5-year DSD 0 4 (44 %) <0.001*
atotal number of patients included in the analysis was 111
btotal number of patients included in the analysis was 68
ctotal number of patients included in the analysis was 39
dtotal number of patients included in the analysis was 28
*p < 0.05 was regarded as statistically significant, and highlighted in boldsface
when present
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suitable prognostic marker for this subgroup of patients
[23]. In the present study we found a highly significant
correlation between the expression of plectin and uPAR.
However, in contrast to uPAR, high expression of plectin
correlated significantly with DSD in all patients with
non-metastatic disease, and not only the T1N0
subgroup.
Most of the tumor cells that expressed plectin also
expressed uPAR. It has previously been suggested that
increased expression of uPAR in tumor cells is associ-
ated with EMT [27, 29, 39]. Little is known about plectin
and EMT, but the formation of plectin-containing podo-
somes has been proposed as a first step towards EMT in
OSCC [40].
Conclusion
The present study has shown that low expression of
plectin predict a favorable outcome for patients with
non-metastatic disease. Furthermore, all patients with
T1N0 disease and low expression of plectin, survived for
more than 5 years. Although the results must be vali-
dated in larger cohorts, they suggest plectin as a promis-
ing prognostic biomarker, which may be used to guide
the treatment stratification for patients with non-
metastatic OSCC.
Fig. 4 Scatter plot of uPAR and plectin score for the whole cohort. There was a significant correlation (p = 0.01) between the plectin and the
uPAR score. The light grey lines in the figure represent the 95 % confidence interval
Fig. 5 Immunofluorescence staining of oral squamous cell
carcinoma tissue. The majority of the cells were positive for both
plectin and uPAR. Plectin (green) is located mainly at the plasma
membrane and the periphery of the cell, while uPAR (red) is
more prominent in the cytoplasmic part of the cells. Plectin is
highly expressed in the wall of blood vessels (asterix)
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